NSE: TORNTPHARM | BSE: 500420

Expensive Performer

Download real time

3314.20 -25.20 (-0.75%)

345.7K NSE+BSE Volume

NSE 11 Jul, 2025 3:31 PM (IST)

112,167.6

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Torrent Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for TORNTPHARM, BSE:500420 Torrent Pharmaceuticals Ltd.

Search Inside the pdf :

Torrent Pharmaceuticals Ltd.

01 Jul 2025

3314.20

-0.75%

Acquisition of JB Pharma to aid scale in India; watchful of synergies

Hold: Torrent Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Torrent Pharma (Torrent) is acquiring 49.2% stake in JB Pharma from KKR (46.4%) and employees (2.8%) at INR 1,600/share (aggregate value of INR 119.2bn, to be funded through debt).

ICICI Securities Limited increased Hold price target of Torrent Pharmaceuticals Ltd. to 3500.0 on 01 Jul, 2025.

Torrent Pharmaceuticals Ltd.

01 Jul 2025

3314.20

-0.75%

Torrent Pharmaceuticals (TRP IN) Event Update Acquires JB...

Accumulate: Torrent Pharmaceuticals Ltd.

Target

Prabhudas Lilladhar

chronic therapies and opens up many newer therapeutic areas. The deal also adds JBCP's CDMO vertical, offering diversification and growth optionality. The acquisition is likely to be debt-funded requiring Rs 122bn to fund acquisition upfront. We see JBCP current OPM of 2728% to scale to 31-32% (similar to current TRP margins) via sourcing efficiencies, cost rationalization, and pricing actions on keys brands. Historically TRP have managed to integrate...

Torrent Pharmaceuticals Ltd. is trading above all available SMAs

Torrent Pharmaceuticals Ltd.

30 Jun 2025

3314.20

-0.75%

JB Chem deal enhances domestic formulation offerings

Neutral: Torrent Pharmaceuticals Ltd.

Target

Motilal Oswal

Torrent Pharma (TRP) is set to acquire a controlling stake in JB Chemicals and Pharmaceuticals (JBCP). The deal is at an equity valuation of INR256b (on a fully diluted basis).

Torrent Pharmaceuticals Ltd. is trading above all available SMAs

Torrent Pharmaceuticals Ltd.

21 May 2025

3314.20

-0.75%

Torrent Pharmaceuticals (TRP IN) Q4FY25 Result Update In-line...

Accumulate: Torrent Pharmaceuticals Ltd.

Target

Prabhudas Lilladhar

Torrent Pharma's (TRP) Q4FY25 adjusted EBITDA was broadly in line with our estimates. Our FY26/ FY27E EBITDA stands reduced marginally by 1-3%. TRP reported Rs 80bn (75% of total sales) worth of highly profitable branded formulation sales spread across India, Brazil and RoW markets. Curatio acquisition has been scaling up well with sharp margin improvement since acquisition. We expect 15% EBITDA CAGR and 27% PAT CAGR over FY25-27E with healthy RoE of +30%. At CMP, stock is trading at 22x EV/EBITDA/35x P/E...

Torrent Pharmaceutic.. has an average target of 3720.40 from 6 brokers.

Torrent Pharmaceuticals Ltd.

21 May 2025

3314.20

-0.75%

BP Equities Q4FY25 Result Update Torrent Pharmaceuticals Ltd

Results Update: Torrent Pharmaceuticals Ltd.

BP Wealth

Torrent Pharmaceuticals Ltd. is trading above all available SMAs

Torrent Pharmaceuticals Ltd.

25 Jan 2025

3314.20

-0.75%

DF, lower interest/tax drive earnings

Neutral: Torrent Pharmaceuticals Ltd.

Target

Motilal Oswal

Torrent Pharma (TRP) delivered largely in line earnings in 3QFY25. The superior performance in domestic formulation (DF) was offset by currency headwinds in Brazil and zero insulin CMO sales.